Ep. 180 - ASCO, Neuropsych & the IRA

BioCentury This Week

Two Phase I checkpoint inhibitor readouts due at ASCO 2023 are bringing excitement back to immuno-oncology, said BioCentury’s Lauren Martz on the latest BioCentury This Week podcast. Martz and her editorial team colleagues discuss what stands out about the data for LAG3 inhibitor fianlimab from Regeneron and anti-TIGIT mAb tiragolumab from Genentech.
The editors also break down takeaways from BioCentury's conversation on precision neuropsychiatry with Husseini Manji, co-chair of the U.K. Mental Health Mission, and assess BIO’s call for CMS to provide more clarity about its plans for implementing provisions in the Inflation Reduction Act that give some small biotechs a temporary exemption from Medicare drug price negotiation. This week’s podcast is sponsored by Cancer Research Horizons.

Reach us by sending a text

2023-05-30 19 min 4 chapters

Available Results

Generated results are saved to the knowledge database for reuse and search.

No generated results are available for this episode yet.

Extract Knowledge

Pick what you want extracted first. Model, scope, and chapter options appear after a template is selected.

Generated results for public episodes are saved to the knowledge database so they can be reused and searched later.
No transcript is available for this episode yet.
Sign in to generate a transcript for review.
Sign in